Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
P/B ratio for Summit Therapeutics Inc. (SMMT)
P/B ratio as of 2023: 20.82
According to Summit Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 20.82. At the end of 2022 the company had a P/B ratio of 6.49.
P/B ratio history for Summit Therapeutics Inc. from 2003 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 20.82 |
| 2022 | 6.49 |
| 2021 | 2.98 |
| 2020 | 4.11 |
| 2019 | 3.35 |
| 2018 | 1.57 |
| 2017 | 45.00 |
| 2016 | -117.33 |
| 2015 | 12.56 |
| 2014 | 11.88 |
| 2013 | 3.81 |
| 2012 | 22.55 |
| 2011 | 304.27 |
| 2010 | 181.75 |
| 2009 | 32.35 |
| 2008 | 30.39 |
| 2007 | 4.54 |
| 2006 | 4.71 |
| 2005 | 7.67 |
| 2004 | 4.79 |
| 2003 | 747.02 |